Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Trial of Investigational Dulaglutide Doses in T2D on Metformin
NCT02973100Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2016
- Primary completion
- Jul 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 6
01
Overview
Phase 2, randomised, double-blind trial of dulaglutide biosimilar 14028 injection in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Change From Baseline in Hemoglobin A1c at 18 weeks. Started Dec 2016; status: completed.
02
Drugs
dulaglutide biosimilar 14028 injection
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02973100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02973100.